Have a feature idea you'd love to see implemented?
Let us know!
GUTS Fractyl Health Inc.
Price (delayed)
$2.06
Market cap
$99.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.19
Enterprise value
$77.35M
We are a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. Despite advances in treatment over the last
Highlights
The EPS has surged by 71% year-on-year and by 43% since the previous quarter
GUTS's gross margin is up by 38% year-on-year and by 13% since the previous quarter
Fractyl Health's equity has soared by 116% YoY but it has decreased by 29% from the previous quarter
GUTS's gross profit is up by 18% year-on-year but it is down by 8% since the previous quarter
GUTS's quick ratio is down by 25% since the previous quarter
The revenue has declined by 18% since the previous quarter and by 14% year-on-year
Key stats
What are the main financial stats of GUTS
Market
Valuations
Earnings
Shares outstanding
48.1M
Market cap
$99.08M
Enterprise value
$77.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.96
Price to sales (P/S)
1,018.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
797.43
Revenue
$97,000
EBIT
-$62.9M
EBITDA
-$60.92M
Free cash flow
-$60.75M
Per share
Balance sheet
Liquidity
EPS
-$12.19
Free cash flow per share
-$1.27
Book value per share
$1.05
Revenue per share
$0
TBVPS
$2.65
Total assets
$126.92M
Total liabilities
$76.6M
Debt
$62.93M
Equity
$50.32M
Working capital
$71.93M
Debt to equity
1.25
Current ratio
5.58
Quick ratio
5.39
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-62,800%
Gross margin
46.4%
Net margin
-64,849.5%
Operating margin
-83,816.5%
Return on assets
-53.8%
Return on equity
N/A
Return on invested capital
-65%
Return on capital employed
-56.6%
Return on sales
-64,849.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GUTS stock price
How has the Fractyl Health stock price performed over time
Intraday
0%
1 week
-1.44%
1 month
-21.07%
1 year
N/A
YTD
N/A
QTD
-18.58%
Financial performance
How have Fractyl Health's revenue and profit performed over time
Revenue
$97,000
Gross profit
$45,000
Operating income
-$81.3M
Net income
-$62.9M
Gross margin
46.4%
Net margin
-64,849.5%
The operating margin has dropped by 92% year-on-year and by 40% since the previous quarter
The company's operating income has shrunk by 65% YoY and by 14% QoQ
GUTS's net margin is down by 39% since the previous quarter and by 7% year-on-year
GUTS's gross margin is up by 38% year-on-year and by 13% since the previous quarter
Growth
What is Fractyl Health's growth rate over time
Valuation
What is Fractyl Health stock price valuation
P/E
N/A
P/B
1.96
P/S
1,018.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
797.43
The EPS has surged by 71% year-on-year and by 43% since the previous quarter
Fractyl Health's equity has soared by 116% YoY but it has decreased by 29% from the previous quarter
The revenue has declined by 18% since the previous quarter and by 14% year-on-year
Efficiency
How efficient is Fractyl Health business performance
The ROA has soared by 64% YoY and by 10% from the previous quarter
GUTS's return on invested capital is up by 44% year-on-year but it is down by 4.5% since the previous quarter
The return on sales has declined by 39% since the previous quarter and by 7% year-on-year
Dividends
What is GUTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GUTS.
Financial health
How did Fractyl Health financials performed over time
Fractyl Health's total assets is 66% higher than its total liabilities
Fractyl Health's total assets has surged by 124% YoY but it has decreased by 13% QoQ
GUTS's quick ratio is down by 25% since the previous quarter
GUTS's debt is 25% greater than its equity
Fractyl Health's equity has soared by 116% YoY but it has decreased by 29% from the previous quarter
Fractyl Health's debt to equity has increased by 44% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.